Phase 3b open-label design, 751 adults with obesity but without T2D, randomized 1:1 to max tolerated dose of tirzepatide (10 or 15 mg) or max tolerated dose of semaglutide (1.7 or 2.4 mg) for 72 weeks, both on top of behavioral support
Ipamorelin mimics the action of ghrelin and selectively stimulates growth hormone release, while CJC-1295 No DAC extends the duration of growth hormone release
And with retatrutide, current status matters a lot
If your weekly dose is 1.0 mg at 5 mg/mL (20 units), a split protocol would be 0.5 mg (10 units) twice per week
Over ten million people are eligible because of a combination of being overweight and having ever been told that they have another weight-related risk factor
Not surprisingly, ALA could alleviate all of these deleterious changes in aged kidneys [136,137,138]